Yashoda Hospitals opens world-class Biplane Neuro Cath lab for brain stroke
It launched the most advanced "DTAS" (Direct to Angio Suite) & State of the art ‘Neuro-Angio’ technology
It launched the most advanced "DTAS" (Direct to Angio Suite) & State of the art ‘Neuro-Angio’ technology
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
Combination of hardware and data analytics software improves real-time and remote patient monitoring; digitizes and automates time-consuming and critical tasks for medical personnel, reducing administrative tasks by 35 per cent
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
This unique record was made possible by collating hard copies of the books in a structured manner
Subscribe To Our Newsletter & Stay Updated